10-K: Edgewise Therapeutics Advances Pipeline, Reports 2025 FY Results

Edgewise Therapeutics, Inc. filed its annual 10-K report for the fiscal year ended December 31, 2025, detailing significant progress in its muscular dystrophy and cardiac disease clinical programs, alongside increased net losses and ongoing capital requirements.

Summary

• Edgewise Therapeutics is a late-stage clinical biopharmaceutical company focused on severe muscle diseases, leveraging a proprietary muscle-focused drug discovery platform.
• Sevasemten, an orally administered fast myofiber myosin inhibitor, is in multiple late-stage clinical trials for Becker muscular dystrophy (Becker) and Duchenne muscular dystrophy (Duchenne), including a pivotal cohort (GRAND CANYON) for Becker.
• Sevasemten received FDA Fast Track designation for Duchenne in February 2024, and Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) for Duchenne and Becker in November 2023.
• Positive 24-month data from the ARCH trial showed sevasemten stabilized NSAA scores and significantly decreased muscle damage biomarkers (CK and TNNI2) in Becker patients.
• Topline data from the CANYON Phase 2 trial showed a 28% average decrease in CK and a 77% decrease in TNNI2 in sevasemten-treated Becker patients over months 6-12, with a trend towards 1.1 point NSAA improvement versus placebo.
• Enrollment for the GRAND CANYON pivotal cohort in Becker was completed in February 2025, and encouraging observations were reported from Phase 2 LYNX and FOX trials in Duchenne patients in June 2025.
• EDG-7500, a novel oral cardiac sarcomere modulator, is in a multipart Phase 2 trial (CIRRUS-HCM) for obstructive (oHCM) and nonobstructive (nHCM) hypertrophic cardiomyopathy.
• CIRRUS-HCM Part A data showed 67% mean reduction in resting LVOT pressure gradient and 55% mean reduction in provokable LVOT-G in oHCM patients (100/200 mg doses) without meaningful changes in LVEF.
• CIRRUS-HCM Part B (oHCM) demonstrated a 71% mean reduction in resting LVOT-G, 58% mean reduction in provokable LVOT-G, and a 62% mean reduction in NT-proBNP at the 100 mg dose, with significant improvements in KCCQ-OSS (23 points) and NYHA functional class (78% improved by ≥1 class).
• CIRRUS-HCM Part C (nHCM) showed a 42% mean reduction in NT-proBNP at the 100 mg dose, also without meaningful LVEF reductions.
• EDG-15400, a novel small molecule for heart failure with preserved ejection fraction (HFpEF), is currently in a Phase 1 trial of healthy adults.
• The company reported a net loss of $167.8 million for the year ended December 31, 2025, compared to $133.8 million in 2024, with an accumulated deficit of $546.4 million.
• As of December 31, 2025, cash, cash equivalents, and marketable securities totaled $530.1 million, expected to fund operations for at least the next 12 months.
• Research and development expenses increased by $24.4 million to $151.4 million in 2025, primarily due to increased clinical activity and personnel costs.
• General and administrative expenses increased by $8.2 million to $40.0 million in 2025, mainly due to personnel-related costs.
• The company ceased to be an emerging growth company and a smaller reporting company as of December 31, 2024, increasing compliance requirements.
• R. Michael Carruthers transitioned from Chief Financial Officer on November 10, 2025, to an advisor role until January 31, 2026, in anticipation of retirement.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report due to significant clinical progress across multiple lead programs, particularly the positive data for sevasemten and EDG-7500, and the completion of key trial enrollments, which de-risks future development. While net losses increased, this is typical for a clinical-stage biopharmaceutical company, and the strong cash position provides runway.

Positives

• Sevasemten demonstrated sustained disease stabilization and functional improvement trends in Becker muscular dystrophy patients over 24 months in the ARCH trial, with significant reductions in muscle damage biomarkers (CK and TNNI2).
• The CANYON Phase 2 trial for sevasemten met its primary endpoint, showing a significant 28% average decrease in CK and a 77% decrease in TNNI2 in Becker patients, with positive trends in NSAA scores.
• Enrollment for the pivotal GRAND CANYON cohort of sevasemten in Becker was completed in February 2025, moving closer to potential marketing authorization.
• Encouraging observations from Phase 2 LYNX and FOX trials for sevasemten in Duchenne muscular dystrophy patients support the potential for functional benefit.
• EDG-7500 showed significant reductions in resting (67%) and provokable (55%) LVOT pressure gradients in oHCM patients in CIRRUS-HCM Part A, and further reductions in Part B (71% resting, 58% provokable) at the 100 mg dose.
• EDG-7500 treatment resulted in robust reductions in NT-proBNP, a key biomarker of heart failure, in both oHCM (62% reduction) and nHCM (42% reduction) patients, indicating potential broad therapeutic utility.
• EDG-7500 achieved gradient and biomarker reductions without meaningful changes or reductions in Left Ventricular Ejection Fraction (LVEF) below 50%, suggesting a differentiated and potentially safer profile compared to other cardiac myosin inhibitors.
• Significant improvements in functional measures like the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS) (23 points) and NYHA functional class (78% improved by ≥1 class) were observed with EDG-7500 in oHCM patients.
• The company maintains a strong cash, cash equivalents, and marketable securities balance of $530.1 million as of December 31, 2025, providing funding for at least the next 12 months.
• Successful capital raise of $187.1 million net proceeds from an underwritten registered direct offering in April 2025 strengthens the financial position.
• The proprietary muscle-focused drug discovery platform continues to generate a pipeline of precision medicine product candidates, including EDG-15400 and the EDG-003 program.

Negatives

• The company incurred a significant net loss of $167.8 million for the year ended December 31, 2025, an increase from $133.8 million in 2024.
• The accumulated deficit reached $546.4 million as of December 31, 2025, reflecting a history of substantial operating losses.
• No products are currently approved for commercial sale, and the company has not generated any revenue to date, relying entirely on financing activities.
• Substantial additional capital will be required to fund operations through regulatory approval and commercialization, posing future dilution risks to stockholders.
• The company is highly dependent on the success of its lead product candidates, sevasemten and EDG-7500, and failure in their development or approval would significantly harm the business.
• Clinical drug development is a lengthy, expensive, and uncertain process, with a high risk of failure, and early-stage results may not be predictive of later success.
• Product candidates may cause serious adverse events, toxicities, or undesirable side effects, which could prevent regulatory approval or limit commercial potential.
• The company faces significant competition from major multinational pharmaceutical and biotechnology companies with greater financial and development resources, and some competitor products have already received approval or are in late-stage development.
• Competitors' exon-skipping therapies (AMONDYS 45, VYONDYS 53, VILTEPSO) have recently missed primary endpoints in confirmatory studies, and Translarna's EU marketing authorization was removed, highlighting the challenges in the Duchenne market.
• Sarepta's Elevidys gene therapy for Duchenne had its indication revised and received black box warnings for liver injuries in November 2025, indicating safety concerns in the competitive landscape.
• Bristol-Myers Squibb's mavacamten failed to meet primary endpoints in its Phase 3 study for nonobstructive HCM, underscoring the difficulty in developing therapies for this condition.
• Reliance on third-party contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) for manufacturing and clinical trials introduces risks related to supply, quality, and adherence to schedules and regulations.
• The patient populations for Duchenne, Becker, and Limb-girdle muscular dystrophy are small, making patient identification and market penetration critical and potentially challenging.
• The company's computer systems, or those of its third-party partners, are vulnerable to cybersecurity threats, which could lead to data breaches, operational disruptions, and significant costs.
• The company's operations are vulnerable to interruptions from natural disasters, public health pandemics, and geopolitical events, which could cause delays and increased costs.
• Changes in U.S. and foreign patent laws, or challenges to existing patents, could diminish the value of intellectual property and competitive advantage.

Risks

• We have a limited operating history and no products approved for commercial sale, making it difficult to evaluate our current business and likelihood of success.
• We have incurred significant net losses since inception and expect to continue to incur substantial net losses for the foreseeable future, requiring substantial additional capital.
• Our ability to generate revenue and achieve profitability depends significantly on our ability to successfully discover, develop, obtain regulatory approval for, and commercialize our product candidates.
• We are substantially dependent on the success of our lead product candidates, sevasemten and EDG-7500, and failure to complete their development or obtain approval would harm our business.
• Clinical drug development is a lengthy, expensive, and uncertain process, and the results of preclinical studies and early clinical trials may not be predictive of future results.
• Our product candidates may cause serious adverse events, toxicities, or other undesirable side effects, which could prevent regulatory approval, limit commercial potential, or result in negative consequences.
• Delays or difficulties in patient enrollment and/or maintenance in clinical trials could delay or prevent regulatory submissions or marketing approvals.
• Our limited resources are currently focused on sevasemten and EDG-7500, potentially causing us to fail to capitalize on other indications or product candidates that may be more profitable.
• We face significant competition from companies with greater resources and more effective, safer, or less expensive products, which could negatively impact our commercial opportunities.
• Interim, topline, and preliminary data from our clinical trials may change as more patient data becomes available and are subject to audit and verification procedures.
• We may not be successful in our efforts to develop a proprietary drug discovery platform to build a pipeline of product candidates.
• Developing product candidates in combination with other therapies exposes us to additional risks, including tolerability issues and regulatory challenges with the combination therapies.
• The manufacture of drugs is complex, and our third-party manufacturers may encounter difficulties in production, leading to supply delays or prevention.
• Changes in methods of product candidate manufacturing or formulation may result in additional costs or delays.
• Our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors, and others in the medical community.
• The patient populations for Duchenne, Becker, and LGMD are small and not precisely established, and if actual numbers are smaller than estimated, revenue and profitability may be adversely affected.
• The regulatory approval processes of the FDA, EMA, and other comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable.
• Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees.
• Our success depends on our ability to protect our intellectual property and proprietary technologies, and patent terms may be inadequate.
• Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties.
• We rely on third parties to conduct our clinical trials and for manufacturing, and their unsatisfactory performance could harm our business.
• Our reliance on third parties may require us to share trade secrets, increasing the risk of discovery or misappropriation by competitors.
• Future acquisitions or strategic partnerships may increase capital requirements, dilute stockholders, cause debt, or assume contingent liabilities.
• Our computer systems, or those of our third parties, may fail or suffer security or data privacy breaches, leading to costs, loss of revenue, and operational disruption.
• Our operations are vulnerable to interruption by fire, earthquakes, power loss, telecommunications failure, terrorist activity, pandemics, and other events beyond our control.
• Our business may become subject to economic, political, regulatory, and other risks associated with international operations, including trade policies and geopolitical conflicts.
• Inflation in the global economy could negatively impact our business and results of operations.
• We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
• Intellectual property discovered through government-funded programs may be subject to federal regulations such as march-in rights and a preference for U.S.-based companies.
• Our affiliated principal stockholders and management own a significant percentage of our stock and can exert significant control over matters subject to stockholder approval.
• Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.
• Our operating results may fluctuate significantly, making future results difficult to predict and potentially causing them to fall below expectations.
• We incur significantly increased costs and devote substantial management time as a result of operating as a public company, and failure to maintain proper internal controls could impair our ability to produce accurate financial statements.
• We do not intend to pay dividends on our common stock in the foreseeable future, so any returns will be limited to the value of our common stock.
• Provisions in our organizational documents and Delaware law might discourage, delay, or prevent a change in control of our company or changes in our management.

Future Outlook

The company expects to continue incurring significant expenses and increasing operating losses for the foreseeable future as it advances its product candidates through clinical development and seeks regulatory approval. Current cash, cash equivalents, and marketable securities are projected to fund operations for at least the next 12 months. The company plans to report initial CIRRUS-HCM Part D data and EDG-15400 Phase 1 topline results in the first half of 2026, and initiate an EDG-15400 Phase 2 trial in HFpEF in the second half of 2026. Discussions with the FDA and European Medicines Agency regarding marketing authorization filing strategies for sevasemten in Becker are ongoing.

Management Comments

• "Our mission is to discover new medicines that improve the lives of people facing serious muscle disease."
• "At Edgewise, we appreciate the life-limiting impact of serious muscle diseases. Our science-driven culture places patients first as we start with their unmet needs and then work towards developing therapies to help address the significant challenges of serious muscle diseases."
• "The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases."

Industry Context

StockSavvy.ai notes that the Duchenne and Becker muscular dystrophy treatment landscape is highly competitive, with several gene therapies and exon-skipping drugs facing challenges (e.g., VILTEPSO, AMONDYS 45, VYONDYS 53 missing endpoints, Elevidys black box warnings). Edgewise's sevasemten, with its novel mechanism of action and positive clinical data, aims to differentiate itself as a foundational therapy, potentially complementing existing or emerging treatments. In HCM, the market is also competitive with established CMIs like CAMZYOS and MYQORZO, but EDG-7500's differentiated profile (less impact on LVEF, potential for fixed-dose regimens) could address unmet needs, especially in nHCM where approved therapies are lacking. The failure of BMS's mavacamten in nHCM highlights this opportunity.

Comparison to Industry Standards

• **Duchenne/Becker Muscular Dystrophy**: Sevasemten shows sustained disease stabilization and functional improvement trends (NSAA, CK, TNNI2 reduction) in Becker and Duchenne, positioning it as a novel, mutation-agnostic approach.
• **Sarepta Therapeutics (EXONDYS 51, AMONDYS 45, VYONDYS 53)**: Exon-skipping therapies with accelerated approval, but AMONDYS 45 and VYONDYS 53 missed primary endpoints in confirmatory studies in November 2025, potentially affecting their accelerated FDA approval.
• **Nippon Shinyaku Co. Ltd. (VILTEPSO)**: Exon-skipping therapy, confirmatory study in May 2024 showed no statistical significance in function.
• **PTC Therapeutics (Translarna)**: Conditionally approved in EU/Brazil for nonsense mutation Duchenne, but European Commission adopted negative opinions for renewal in March 2025, and application to FDA was withdrawn in February 2026.
• **Sarepta Therapeutics (Elevidys)**: Microdystrophin gene therapy, received full FDA approval in June 2024 for ambulatory Duchenne (4+ years), but indication revised in November 2025 to limit to ambulatory and added black box warnings for liver injuries.
• **Italfarmaco Group (Duvyzat)**: Nonsteroidal HDAC inhibitor, approved by FDA in March 2024 for Duchenne (6+ years), conditional EU approval June 2025. Phase 2 data for givinostat in Becker (June 2021) did not show significant difference.
• **Avidity Biosciences (del-zota)**: Announced positive topline Phase 1/2 data in September 2025 for exon 44 skipping Duchenne.
• **Dyne Therapeutics (zeleciment rostudirsen)**: Announced positive topline Phase 1/2 data in December 2025 for exon 51 skipping Duchenne.
• **Capricor Therapeutics, Inc. (Deramiocel)**: ODD granted for Becker in June 2025, under regulatory review.
• **Hypertrophic Cardiomyopathy (HCM)**: EDG-7500 demonstrated significant reductions in LVOT gradient and NT-proBNP without meaningful LVEF reduction, suggesting a potentially safer profile compared to CMIs.
• **Bristol-Myers Squibb (CAMZYOS/mavacamten)**: CMI, approved by FDA in April 2022 for oHCM. Phase 3 study in nHCM failed to meet dual primary endpoints in April 2025.
• **Cytokinetics (MYQORZO/aficamten)**: CMI, received FDA approval in December 2025 for oHCM. Exploring in ongoing Phase 3 nHCM trial.
• **Imbria Pharmaceuticals (ninerafaxstat)**: pFOX inhibitor, announced Phase 2 nHCM topline results in November 2023, initiated Phase 2b nHCM trial in Q2 2025.
• **Tenaya Therapeutics (TN-201)**: Myosin binding protein C3-targeting gene therapy, interim Phase 1b/2 results announced December 2024.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.

Related Party Transactions

• Information regarding certain relationships and related transactions will be contained in the definitive proxy statement for the 2026 annual meeting of stockholders, to be filed within 120 days after December 31, 2025. No material related party transactions were explicitly detailed in this 10-K filing.

Stakeholder Impact

• **Shareholders**: Potential for stock price appreciation due to positive clinical trial results and pipeline advancement, but also risk of dilution from future capital raises and volatility due to significant net losses and competitive pressures.
• **Patients**: Potential for new, disease-modifying therapies for severe muscle diseases like Duchenne, Becker, HCM, and HFpEF, addressing high unmet medical needs. Clinical trial progress offers hope for improved treatment options.
• **Employees**: Continued growth in headcount, particularly in research and development, with stock-based compensation as an incentive. However, the company faces competition for skilled personnel.
• **Third-party Payors**: Will need to establish coverage and adequate reimbursement for any approved products, which is a complex and time-consuming process, potentially impacting market acceptance and revenue.
• **Regulatory Authorities**: Ongoing engagement with FDA and EMA for marketing authorization, subject to evolving regulatory frameworks and increased scrutiny, especially regarding accelerated approval pathways and post-marketing requirements.

Next Steps

• Engage FDA and European Medicines Agency about marketing authorization filing strategies for sevasemten in Becker.
• Report initial CIRRUS-HCM Part D data in the first half of 2026.
• Report EDG-15400 Phase 1 topline results in the first half of 2026.
• Initiate EDG-15400 Phase 2 trial in participants with HFpEF in the second half of 2026.

Key Dates

Recommendation

Edgewise Therapeutics shows promising clinical progress with its lead candidates, sevasemten and EDG-7500, addressing high unmet medical needs in muscular dystrophies and cardiac diseases. The positive topline data and advancement into pivotal/late-stage trials are significant de-risking events. However, the company continues to incur substantial net losses and will require significant additional capital for commercialization, which introduces future dilution risk. The competitive landscape is also intense. Given the strong clinical momentum balanced against the financial burn and future funding needs, a "hold" recommendation is appropriate for investors to monitor further clinical outcomes and commercialization strategies.

Keywords

Muscular Dystrophy, Duchenne, Becker, Hypertrophic Cardiomyopathy, HCM, Heart Failure with Preserved Ejection Fraction, HFpEF, Sevasemten, EDG-7500, EDG-15400, Biopharmaceutical, Clinical Trials, Orphan Drug, Rare Pediatric Disease, Sarcomere Modulator, Myosin Inhibitor, Drug Discovery, SEC Filing, 10-K